Patient characteristics
| . | N (%)/median (range) . | P value . | |
|---|---|---|---|
| Vaccinated (n = 243) . | Unvaccinated (n = 175) . | ||
| Age, y | 67 (24-89) | 56 (19-88) | < .001 |
| Gender | |||
| Female | 94 (39) | 71 (41) | .70 |
| Male | 149 (61) | 104 (59) | |
| Modified CCI∗ | 3 (0-8) | 2 (0-14) | < .001 |
| Disease type | |||
| BCL | 131 (54) | 63 (36) | <.001 |
| Chronic lymphocytic leukemia | 54 (23) | 30 (17) | |
| Low-grade BCL | 44 (18) | 16 (9) | |
| High-grade BCL | 33 (14) | 17 (9) | |
| Plasma cell dyscrasia | 37 (15) | 18 (10) | |
| Other | 75 (31) | 94 (54) | |
| Myelodysplastic syndrome/acute myeloid leukemia | 31 (13) | 37 (21) | |
| Myeloproliferative neoplasm/chronic myeloid leukemia | 18 (7) | 22 (13) | |
| Acute lymphoblastic leukemia | 8 (3) | 15 (9) | |
| Hodgkin lymphoma | 8 (3) | 10 (6) | |
| T-cell leukemia/lymphoma | 7 (3) | 5 (5) | |
| Disease/treatment status | |||
| Untreated | 31 (13) | 30 (17) | .34 |
| In remission | 150 (62) | 97 (55) | |
| With active disease | 62 (26) | 48 (27) | |
| On active therapy | 121 (50) | 86 (49) | .90 |
| Received stem cell transplantation/cellular therapy | 46 (19) | 48 (27) | .04 |
| Baseline laboratory values† | |||
| White blood cell, 103/μL | 5.3 (0.2-102.3) | 5.4 (0.1-200.7) | .88 |
| Absolute neutrophil count, 103/μL | 3.1 (0.0-41.1) | 3.0 (0.0-32.6) | .77 |
| Hemoglobin, g/dL | 12.6 (5.5-17.5) | 11.8 (6.0-16.9) | .051 |
| Platelets, 103/μL | 177 (1-600) | 162 (1-747) | .21 |
| Creatinine, mg/dL | 1.0 (0.4-5.1) | 0.9 (0.3-9.1) | .88 |
| Immunoglobulin G, mg/dL‡ | 730 (71-5230) | 772 (134-2797) | .82 |
| No. of vaccine doses received§ | |||
| 1 | 66 (27) | — | — |
| 2 | 163 (68) | — | — |
| 3 | 12 (5) | — | — |
| . | N (%)/median (range) . | P value . | |
|---|---|---|---|
| Vaccinated (n = 243) . | Unvaccinated (n = 175) . | ||
| Age, y | 67 (24-89) | 56 (19-88) | < .001 |
| Gender | |||
| Female | 94 (39) | 71 (41) | .70 |
| Male | 149 (61) | 104 (59) | |
| Modified CCI∗ | 3 (0-8) | 2 (0-14) | < .001 |
| Disease type | |||
| BCL | 131 (54) | 63 (36) | <.001 |
| Chronic lymphocytic leukemia | 54 (23) | 30 (17) | |
| Low-grade BCL | 44 (18) | 16 (9) | |
| High-grade BCL | 33 (14) | 17 (9) | |
| Plasma cell dyscrasia | 37 (15) | 18 (10) | |
| Other | 75 (31) | 94 (54) | |
| Myelodysplastic syndrome/acute myeloid leukemia | 31 (13) | 37 (21) | |
| Myeloproliferative neoplasm/chronic myeloid leukemia | 18 (7) | 22 (13) | |
| Acute lymphoblastic leukemia | 8 (3) | 15 (9) | |
| Hodgkin lymphoma | 8 (3) | 10 (6) | |
| T-cell leukemia/lymphoma | 7 (3) | 5 (5) | |
| Disease/treatment status | |||
| Untreated | 31 (13) | 30 (17) | .34 |
| In remission | 150 (62) | 97 (55) | |
| With active disease | 62 (26) | 48 (27) | |
| On active therapy | 121 (50) | 86 (49) | .90 |
| Received stem cell transplantation/cellular therapy | 46 (19) | 48 (27) | .04 |
| Baseline laboratory values† | |||
| White blood cell, 103/μL | 5.3 (0.2-102.3) | 5.4 (0.1-200.7) | .88 |
| Absolute neutrophil count, 103/μL | 3.1 (0.0-41.1) | 3.0 (0.0-32.6) | .77 |
| Hemoglobin, g/dL | 12.6 (5.5-17.5) | 11.8 (6.0-16.9) | .051 |
| Platelets, 103/μL | 177 (1-600) | 162 (1-747) | .21 |
| Creatinine, mg/dL | 1.0 (0.4-5.1) | 0.9 (0.3-9.1) | .88 |
| Immunoglobulin G, mg/dL‡ | 730 (71-5230) | 772 (134-2797) | .82 |
| No. of vaccine doses received§ | |||
| 1 | 66 (27) | — | — |
| 2 | 163 (68) | — | — |
| 3 | 12 (5) | — | — |
BCL, B-cell lymphoma.
Modified CCI incorporates all comorbidity variables of the original CCI15 except for solid tumor, leukemia, and lymphoma statuses.
Available in 219 vaccinated and 153 unvaccinated patients.
Available in 180 vaccinated and 115 unvaccinated patients.
Available in 241 vaccinated patients.